Applicant, as named in the Orange Book
Glaxo Grp Ltd
GSK plc · NYSE: GSK
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Breo Ellipta on 11 Apr 2031. 1 products with live protection, 8 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Breo Ellipta NDA 204275 · 3 strengths fluticasone furoate; vilanterol trifenatate | 11 Apr 2031 patent |
Recent events
- Flovent Hfa · First generic approved · ANDA 219602, Glenmark SpecltApproved 3 Mar 2026Detected 25 Oct 2026
- Flovent Hfa · Generic approved · ANDA 219602, Glenmark SpecltApproved 3 Mar 2026Detected 25 Oct 2026
- Breo Ellipta · Exclusivity expires within 90 days PEDExclusivity expires 13 Nov 2026Detected 24 Oct 2026
- Breo Ellipta · Exclusivity expires within 90 days PEDExclusivity expires 13 Nov 2026Detected 24 Oct 2026
Products without listed protection (8)
| Drug | Earliest generic entry |
|---|---|
| Advair Diskus 100/50 NDA 021077 fluticasone propionate; salmeterol xinafoate | open now no listed protection |
| Advair Diskus 250/50 NDA 021077 fluticasone propionate; salmeterol xinafoate | open now no listed protection |
| Advair Diskus 500/50 NDA 021077 fluticasone propionate; salmeterol xinafoate | open now no listed protection |
| Advair Hfa NDA 021254 · 3 strengths fluticasone propionate; salmeterol xinafoate | open now no listed protection |
| Flovent Diskus 100 NDA 020833 fluticasone propionate | open now no listed protection |
| Flovent Diskus 250 NDA 020833 fluticasone propionate | open now no listed protection |
| Flovent Diskus 50 NDA 020833 fluticasone propionate | open now no listed protection |
| Flovent Hfa NDA 021433 · 3 strengths fluticasone propionate | open now no listed protection |